Treatment of Pleural and Peritoneal Effusion with Intracavitary Colloidal Radiogold (Au 198 )

Abstract: Treatment in Internat Medicine Submitted for publication June 5 1959. Department of Medicine and the Radioisotope Center Vanderbilt University School of Medicine. This work was supported in part by grants in aid of research from the American College of Chest Physicians the Don Tobey Fund the Fowler Fund and Graduate Training Grant 2A5129 National Institute of Arthritis and Metabolic Diseases Public Health Service. Rockefeller Foundation Research FeIIow Gdansk Poland (Dr. Dybicki). Assistant Professor of Medicine University of Southern California School of Medicine Los Angeles (Dr. Balchum). Associate Professor of Medicine and Director of the Radioisotope Center Vanderbilt University School of Medicine and Hospital Nashville Tenn. (Dr. Meneely). Summary Intracavitary radiogold was administered to 45 patients with pleural and peritoneal effusions due to local or metastatic malignancy. Thirty-nine of these patients could be completely evaluated. In 22 patients with pleural effusion good results were obtained in 54.5% fair results in an additional 18.2% and failure resulted in the remaining 27 3%. In 17 patients with peritoneal effusions good results were obtained in 58.8% fair results in an additional 17.6% and failure of fluid control resulted in the remaining 23.6%. Compilation of 1 899 instances from the literature of radiogold administration to patients with malignant pleural and peritoneal effusions has indicated that good results have been achieved in 50%. Administration of radiogold is accompanied by few serious side effects and has no real hazards to patient or personnel when used properly. Although only palliative and not curative intracavitary Au198 can successfully relieve the distressing consequences of protein and electrolyte loss in patients with malignant effusions and can result in distinct symptomatic relief. Vanderbilt University Hospital (5) (Dr. Meneely) .

Zurück | Weiter